Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, we are dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV Technologies is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY.

Investor Relations


Sara Blum Sherman
Senior Director
Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

Subscribe
to get the latest
DBV press releases

Press Releases

DocumentYearTerms

08/04/2020 - 7:30 am

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

Download PDF (437 KB)

07/31/2020 - 7:30 am | Finance

DBV Technologies Reports First Half 2020 Financial Results

Download PDF (437 KB)

07/20/2020 - 10:01 pm

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Download PDF (393 KB)